PRINCETON, N.J. / Sep 20, 2023 / Business Wire / Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $0.10 par value common stock of the company. The dividend is payable on November 1, 2023, to stockholders of record at the close of business on October 6, 2023.
In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable on December 1, 2023, to stockholders of record at the close of business on October 31, 2023.
About Bristol Myers Squibb Company
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.
| Last Trade: | US$48.28 |
| Daily Change: | 0.43 0.90 |
| Daily Volume: | 17,550,037 |
| Market Cap: | US$98.010B |
May 06, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
